COVID-19 Critical Intelligence Unit

Daily evidence digest

23 February 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

AstraZeneca single dose efficacy at 90 days, rate reduction in SARS-CoV-2 infection and COVID-19 post Pfizer vaccination, super-spreaders

Peer reviewed journals featured:

- Pooled analysis of four randomised trials of AZD1222 (AstraZeneca) vaccine, including standard single dose efficacy for up to 90 days after vaccination here
- Systematic reviews on:
 - The efficacy and safety of systematic corticosteroids for COVID-19 patients <u>here</u>
 - The impact of COVID-19 super-spreaders <u>here</u>
 - o Neurological manifestations associated with COVID-19 here
 - Diagnostic performance of COVID-19 serological assays during early infection here
- A randomised controlled trial of ivermectin in 62 COVID19 patients in Lagos, Nigeria here
- A modelling study on the durability of immune responses in mild-moderate COVID-19 here
- Observational studies on:
 - The outcomes of a COVID-19 recovery program for hospitalised patients in New York here
 - o The effects of the pandemic on physical and mental health in the UK here
 - o Harnessing peak transmission around symptom onset for COVID-19 here
 - The impact of COVID-19 in hospitals and patients in the US here
- Commentary on:
 - Vaccine prioritisation strategies in Israel and European countries here
 - Sexual orientation, race/ethnicity, and prevalence of COVID-19 comorbidities <u>here</u>
 - Soothing science scepticism here
 - Vaccinating low risk health care employees in the US here
 - A large scale COVID-19 vaccination program in the US here
 - The direct and indirect effects of COVID-19 <u>here</u>
- Editorials on:
 - Prophylactic anticoagulation for patients in hospital with COVID-19 here
 - Under-reporting of SARS-CoV-2 in Africa <u>here</u>



Letters and correspondence discussed:

- Concerns about a delayed second dose of the BNT162b2 (Pfizer) vaccine here
- Case reports of side effects from BNT162b2 (Pfizer) vaccine
 – a recurrence of Bell's Palsy <u>here</u> and morbilliform rash <u>here</u>
- Responses to Oran and Topol's narrative review on the prevalence of asymptomatic SARS-CoV-2 infection here, <a hre
- The risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults here
- Response to an article on serodiagnostics for SARS-CoV-2 <u>here</u> and author's reply <u>here</u>
- Vaccine prioritisation for people with diabetes <u>here</u> and with severe mental illness <u>here</u>
- The meaning of 95% COVID-19 vaccine efficacy <u>here</u>
- SARS-CoV-2 antigen rapid tests in public health responses here
- The need for a new COVID-19 social contract <u>here</u>
- Vaccination rates and acceptance of SARS-CoV-2 vaccination in US healthcare personnel here
- Severe relapse in an immunocompromised patient with persistent SARS-CoV-2 infection here
- Sequelae in adults at 6 months post-COVID-19 infection <u>here</u>
- Population subgroup differences in the use of a COVID-19 chatbot <u>here</u>
- The rationale to continue approving placebo-controlled COVID-19 vaccine trials here
- The risk of SARS-CoV-2 infection in patients with hypothyroidism and hyperthyroidism here
- Delayed-onset myocarditis following COVID-19 here

Pre-peer review articles featured:

- A cohort study of SARS-CoV-2 infection and COVID-19 in Pfizer vaccine recipients in Israel here
- An observational study of risk of failure in hotel quarantine in Australia and New Zealand here
- A survey-based study on changes in vaccine willingness in Australia <u>here</u>
- A cohort study on the duration of acute infection with B.1.1.7 variant (UK / Kent) here
- An observational study on the rise variant B.1.1.7 (UK / Kent) in the elderly in Israel here
- An evaluation on reusing N95 face mask during COVID-19 here
- An audit of CLABSI and CAUTI infections in US hospitals during the COVID-19 pandemic here

Guidance and reports

• The World Health Organization published its COVID-19 weekly epidemiological report here

Click here to subscribe to the daily evidence digest.

Emerging evidence on vaccines and variants of concern is incorporated daily into Living Evidence Tables <u>available here</u>



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.